Sovaldi (sofosbuvir) / Gilead - LARVOL DELTA

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. (PubMed, J Viral Hepat) - "Viraemic patients were treated with 12- or 24-week regimens of sofosbuvir (400 mg) and daclatasvir (60 mg), depending on the fibrosis degree. The model appears feasible in terms of patient-level outcomes, though broader operational feasibility-including resources and scalability-was not formally assessed. Remaining barriers to treatment initiation and follow-up need to be addressed to advance national HCV elimination goals."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan (clinicaltrials.gov) - P=N/A | N=318 | Enrolling by invitation | Sponsor: Queen Mary University of London | Trial completion date: Sep 2025 ➔ Sep 2027 | Trial primary completion date: Sep 2025 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation

Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia (ISPOR-EU 2025) - "The EASE trial showed that an 8-week regimen of ravidasvir/sofosbuvir achieves over 90% sustained virological response, SVR12 and has over 97% adherence among vulnerable populations, proving non-inferior to the 12-week standard. This implementation science evaluation seeks to generate actionable evidence for enhancing Malaysia's hepatitis C elimination model and to provide innovative methodologies relevant to health system interventions in low- and middle-income countries. By yielding findings that inform evidence-based policy decisions, this study facilitates replication in similar contexts aiming for equitable hepatitis C elimination. The resulting framework effectively bridges the gap between policy, evidence, and frontline healthcare delivery, offering a sustainable model for other nations pursuing their HCV elimination goals."

Hepatitis C • Hepatology • Infectious Disease • Inflammation

SOFOSBUVIR BASED REGIMENS ARE EFFECTIVE FOR HEPATITIS C TREATMENT IN PATIENTS WITH END-STAGE RENAL DISEASE IN REAL-LIFE SETTING (AASLD 2025) - "Sofosbuvir in combination with daclatasvir or velpatasvir are highly and equally effective against HCV in CKD patients with eGFR below 30 mL/min."

Clinical • Chronic Kidney Disease • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease

IN VITRO MODEL OF AURKB EXPRESSION LEVELS REGULATION MEDIATED BY SOFOSBUVIR TREATMENT (AASLD 2025) - " Cultures of Huh7 and Huh7.5 hepatoma cell lines were treated with SOF (C22H29N3FO9P) or daclatasvir (DCV) (BMS-790052) at different doses...All SOF-induced effects were reversed in the presence of AZD1152, an inhibitor of AURKB activity, confirming that they were exerted through the AURKB pathway... These results suggest that SOF can induce cell cycle modifications through AURKB activation in in vitro cell models. The effect of these changes in vivo (hepatitis C patients treated with SOF) should be analysed, taking into account that HCV eradication may induce an increase in AURKB per se, due to the inhibitory effect that the viral core protein exerts on AURKB activity."

Preclinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Solid Tumor • AURKB • DUSP1 • EGFR • PDGFRB

SOFOSBUVIR-BASED REGIMEN ACHIEVED HIGH VIROLOGICAL RESPONSE IN NON-GENOTYPED HCV PATIENTS FROM A GENOTYPE 3 HIGH-PREVALENCE REGION OF SOUTHWEST CHINA: A RETROSPECTIVE COHORT STUDY (SAIN-C) (AASLD 2025) - "Patients were treated with Sofosbuvir/Velpatasvir (SOF/VEL) or Ledipasvir/Sofosbuvir (LDV/SOF) ± Ribavirin(RBV) for 12 weeks. SOF-based regimen could achieve high SVR regardless of genotype testing, even in high-prevalence regions of HCV GT3 infection. We believe this simplified strategy could be considered for genotype testing unavailable areas."

Retrospective data • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

Viral Quasispecies Inference from Single Observations-Mutagens as Accelerators of Quasispecies Evolution. (PubMed, Microorganisms) - "Our results reveal that with highly fit HCV quasispecies, sofosbuvir inhibits quasispecies genetic diversity, while mutagenic treatments accelerate maturation, compared to untreated controls...This framework enables robust, quantitative comparisons of quasispecies diversity from single observations, providing valuable insights into viral adaptation and treatment response. The R code and session info with required libraries and versions is provided in the supplementary material."

Journal • Hepatitis C • Infectious Disease • Inflammation

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. (PubMed, Turk J Gastroenterol) - "The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy...The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation. This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication."

Journal • Fatigue • Fibrosis • Hematological Disorders • Hepatitis C • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk. (PubMed, Sci Rep) - "A total of 483 patients treated with sofosbuvir-based direct-acting antivirals (DAAs) were enrolled and followed for a mean duration of 38.8 months...The hazard ratio was 0.28 (95% CI: 0.1-0.73, P = 0.01) in the "Stable normal" group, compared to the "Elevation" group. The findings suggest that normalization of AFP levels or stable normal levels after treatment are associated with a reduced risk of HCC."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor • AFP

In-silico screening of small compounds against Lassa fever haemorrhagic virus nucleoprotein. (PubMed, Sci Rep) - "Retrieved ligands: 5-(Methylene) evodiamine, N-(2-Fluorobenzoyl) evodiamine, N-[[2-(3-chlorophenyl)-5-(trifluoromethyl) pyrazol-3-yl]methyl]-2-(1-methyl-2,3-dihydroindol-5-yl) propanamide (NCTPMMDP), lauric acid, and sofosbuvir, and the target protein, 3MX5, were prepared and utilised for docking, molecular dynamics simulation, ADMET profiling, and DFT using standard protocols...The DFT result showed that, apart from lauric acid, all the test ligands possess small energy gaps indicative of high reactivity. Put together, these findings indicate that the test ligands possess anti-LHFV potential that merits further in vivo and in vitro evaluations."

Journal • Preclinical • Hematological Disorders • Infectious Disease

Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review. (PubMed, New Microbes New Infect) - "Favipiravir, ribavirin, and sofosbuvir demonstrated viremia reduction and symptoms improvement in vitro and in vivo experiments...Montelukast and doxycycline exhibited anti-inflammatory effects, contributing to improved clinical outcomes... Currently, there are no studies in humans demonstrating effective treatments against arboviral infections. Although some molecules have shown efficacy in reducing viral titters, further clinical evaluation of promising candidates and the exploration of combination therapies targeting viral replication and host immune-response are needed."

Journal • Review • Chikungunya • Dengue Fever • Infectious Disease

The efficacy and safety of emitasvir phosphate capsules combined with sofosbuvir tablets in the treatment of genotype 1 chronic hepatitis C: A multicenter, real-world study (ChiCTR) - P4 | N=512 | Not yet recruiting | Sponsor: Beijing Ditan Hospital, Capital Medical University; Community Health Association of China

New P4 trial • Real-world evidence • Hepatitis C • Infectious Disease • Inflammation

Identification of potential inhibitors of the main protease from feline infectious peritonitis virus using molecular docking and dynamic simulation approaches. (PubMed, PeerJ) - "Our results show that out of the 15 antiviral and immunomodulatory compounds, the top-ranked inhibitors for the FIPV-Mpro are reference standard inhibitor (N3), Sofosbuvir, and the GS-441524, out of which GS-441524 was suggested as Mpro-inhibitor on the basis of further investigation through molecular dynamics simulation method. Further in vitro and in vivo studies are encouraged to test the efficacy of these identified compounds as potent inhibitors for the Mpro of the FIPV in cats. This study will pave the way for the development of novel drugs that treat FIPV infection in cats."

Journal • Infectious Disease • Novel Coronavirus Disease

Repurposing of Some Nucleoside Analogs Targeting Some Key Proteins of the Avian H5N1 Clade 2.3.4.4b to Combat the Circulating HPAI in Birds: An In Silico Approach. (PubMed, Viruses) - "(3) Molecular docking revealed strong binding affinities for both sofosbuvir and GS441524, particularly with the NA and PB2/CBD protein targets...The MM-GBSA binding free energy calculations further supported these findings, as GS441524 displayed more favorable binding energies compared to several known standard inhibitors, including F0045S for HA, Zanamivir for NA, Rimantadine and Amantadine for M2, and PB2-39 for PB2/CBD...These results further support the potential repurposing of GS441524 as a promising therapeutic candidate against H5N1 avian influenza clade 2.3.4.4b. However, further functional studies are required to validate these in silico predictions and support the inhibitory action of GS441524 against the targeted proteins of H5N1, specifically clade 2.3.4.4b."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Changes in liver stiffness measurements following hepatitis C sustained virologic response among Alaska Native adults treated with sofosbuvir-based direct acting anti-viral therapy. (PubMed, Int J Circumpolar Health) - "Liver function and blood-based estimates of fibrosis also improved. The most important predictor of LSM improvement was pre-treatment fibrosis stage."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Key population-led test and treat for hepatitis C virus infection in Thailand enables rapid initiation of treatment and achieved high virological success rates (IAS-HIV 2025) - "Those who met simplified treatment criteria (absence of advanced fibrosis score, hepatitis B (HBV) co-infection, or other medical concerns) received 12-week oral direct-acting antivirals (DAAs – sofosbuvir 400mg and velpatasvir 100mg once daily). KP-led HCV test-and-treat intervention enabled quick confirmation of active HCV-infection, quick DAAs initiation, and high rates of treatment completion and SVR. Clients referred out for treatment often did not initiate DAAs or did so after significant delays. To increase rates of SVR assessment, barriers for SVR testing should be explored to design and implement targeted interventions."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Structural Basis and Rational Design of Nucleotide Analogue Inhibitor Evading the SARS-CoV-2 Proofreading Enzyme. (PubMed, J Am Chem Soc) - "Nsp14 ExoN exhibited significantly attenuated activity on RNA with sofosbuvir monophosphate (SMP) compared with natural nucleotides, remdesivir/molnupiravir monophosphate, and, in particular, AT-9010 monophosphate (ATMP), which has the same chemically modified ribose moiety as SMP, incorporated at the 3' end. Guided by this hypothesis, two NAs were designed to effectively resist nsp14 ExoN cleavage. These results inform the rational design of anti-CoV NAs."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • ATM

Application of Biomaterials in the Development of Enteric-Coated Luminar Capsule Microneedles for Selective Delivery of Sofosbuvir to the Liver: A Promising Treatment for Hepatitis C. (PubMed, Mol Pharm) - "In vitro and ex vivo permeability studies demonstrated that LUCAMs released 99.32 ± 11.92 and 203.97 ± 19.78 μg/mL SOF within 24 h, respectively. In vivo studies were conducted on two groups, namely, LUCAMs and controls, with measurements taken at 12, 24, and 36 h. The results demonstrated a significant increase in SOF concentration in the liver, reaching 1.26 ± 0.18 μg/mL in the LUCAM group by 36 h, in contrast to the control group, which was only detected at 12 h (0.83 ± 0.13 μg/mL) and not detected at 24 and 36 h. Histopathological analysis confirmed the absence of severe tissue damage, indicating that LUCAMs are a promising approach for enhancing the delivery of SOF to the liver and improving the efficacy of hepatitis C treatment."

Journal • Gastrointestinal Disorder • Hematological Disorders • Hepatitis C • Infectious Disease • Inflammation

A case report of sofosbuvir induced drug eruption and literature review. (PubMed, IDCases) - "Here we report a patient who experienced drug-induced eruption induced by two distinct sofosbuvir-containing regimens. The report includes a thorough analysis and discussion of the case, accompanied by a comprehensive literature review."

Journal • Hepatitis C • Infectious Disease • Inflammation

The Use of Phosphotriesterase in the Synthesis of Enantiomerically Pure ProTide Prodrugs. (PubMed, Chem Biol Interact) - "ProTide nucleotide analogs such as Remdesivir and Sofosbuvir have become an important class of antivirals. The extensive directed evolution of PTE has led to the identification of variants that can selectively hydrolyze the phosphonamidate precursor of the ProTides, allowing the preparation of optically pure ProTides. Importantly, the variant In1W-PTE allows the isolation of the pure RP-isomer while G60A-PTE and W131M-PTE allow the isolation of the pure SP-isomer, thereby facilitating the efficient preparation of either isomer of the final ProTide."

Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Novel Coronavirus Disease

The Role of Ribose Modifications on the Structural Stability of Nucleotide Analogues with α-Thiotriphosphate at the Active Site of SARS-CoV-2 RdRp. (PubMed, J Chem Inf Model) - "For instance, Sofosbuvir with α-thiotriphosphate modification successfully escaped the excision of nsp14/10...Interestingly, chemical modification on the ribose, especially the 1' and 3'-ribose positions, increases the structural stability of analogues through hydrogen bond interactions. Our results revealed nucleotide analogues' structural and dynamical features with "thio" modification at the active site, which may contribute to future drug design or repurposing aimed at the SARS-CoV-2 RdRp."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C-A Systematic Review and Meta-Analysis. (PubMed, Diseases) - "The moderate certainty evidence suggests that adding ribavirin to sofosbuvir-based regimens may not confer benefit in achieving SVR in previously treated individuals with non-genotype 1 HCV but increases the odds of adverse events and treatment discontinuation. More evidence is needed on the effect of additional ribavirin in achieving SVR in individuals with decompensated cirrhosis."

Journal • Retrospective data • Review • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity. (PubMed, Sci Rep) - "Established RdRp inhibitors, including remdesivir, molnupiravir, tenofovir, and sofosbuvir, significantly reduced reporter activity, with remdesivir exhibiting the strongest inhibition. A newly identified RdRp inhibitor was further validated through primer extension polymerase and NMPylation assays, along with virus-based experiments, confirming its inhibitory mechanism. These results highlight the utility of this screening system in identifying effective RdRp-targeting antivirals, reinforcing the strategic importance of RdRp inhibition in combating SARS-CoV-2 and emerging variants."

Journal • Cytomegalovirus Infection • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study. (PubMed, J Int Med Res) - "All patients were treated with sofosbuvir (400 mg once daily) plus daclatasvir (60 mg once daily) for 3 months. In patients with sustained virologic response, autoimmune manifestations persisted in 66 of the 71 (92.9%) patients with an observable rise in posttreatment erythrocyte sedimentation rate and C-reactive protein level (p > 0.01). The predictors of persistence of autoimmune manifestation were age ≥49 years (p = 0.009), female sex (p = 0.026), and tobacco use (p = 0.043).ConclusionDirect-acting antiviral drugs were not associated with a significant short-term change in the prevalence of autoimmune manifestations in patients who had hepatitis C virus infection with sustained virologic response."

Journal • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Oncology • Rheumatology • Solid Tumor • CRP

Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo. (PubMed, Antiviral Res) - "We evaluated combinations of three oral directly acting antiviral drugs (sofosbuvir (SOF), molnupiravir (MPV), and favipiravir (FAV)), which are approved for other indications, against CHIKV, Semliki Forest virus (SFV), Sindbis virus (SINV), and Venezuelan Equine Encephalitis virus (VEEV) in vitro and in vivo. Combining these approved oral nucleoside analogues confers potent suppression of multiple alphaviruses in vitro and in vivo with enhanced control of viral genetic evolution in face of antiviral pressure. These drug combinations may ultimately lead to the development of potent combinations of pan-family alphavirus inhibitors."

Journal • Preclinical • Chikungunya • CNS Disorders • Immunology • Rheumatology